Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 17-deacetylnorgestimate
2. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (17alpha)-
3. Levonorgestrel Oxime
4. Levonorgestrel Oxime, (3e,17alpha)-isomer
5. Levonorgestrel Oxime, (3z,17alpha)-isomer
6. Lngo
7. Progestin Norelgestromin
1. Levonorgestrel Oxime
2. Norplant 3-oxime
3. D-norgestrel 3-oxime
4. 18-methylnorethindrone Oxime
5. 17-deacetylnorgestimate
6. 53016-31-2
7. 17-deacylnorgestimate
8. (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
9. Deacetylnorgestimate
10. Norgestimate Metabolite Norelgestromin
11. Norelgestromin (17-deacetylnorgestimate)
12. Brn 4202099
13. Unii-r0tay3x631
14. Norelgestromin [usan:inn:ban]
15. Rwj 10553
16. Levonorgestrel 3-oxime
17. 17-deacetyl Norgestimate
18. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (17alpha)-
19. R0tay3x631
20. Chembl4791392
21. Dtxsid9046788
22. 13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one Oxime
23. Db06713
24. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (8-alpha,9-beta,10-alpha,13-alpha,14-beta)-
25. 17-deacylnorgestimate17-deacetyl Norgestimate
Molecular Weight | 327.5 g/mol |
---|---|
Molecular Formula | C21H29NO2 |
XLogP3 | 3.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
Exact Mass | 327.219829168 g/mol |
Monoisotopic Mass | 327.219829168 g/mol |
Topological Polar Surface Area | 52.8 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 642 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 1 |
Covalently Bonded Unit Count | 1 |
Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
Norelgestromin is used for contraception and menopausal hormonal therapy transdermally or in combination with ethinyl estradiol as a vaginal ring. Norelgestromin, in combination with ethinyl estradiol inhibits ovulation by suppressing gonadotropins.
Contraceptive Agents, Hormonal
Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)
G03AA13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Norelgestromin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Norelgestromin, including repackagers and relabelers. The FDA regulates Norelgestromin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Norelgestromin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Norelgestromin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Norelgestromin supplier is an individual or a company that provides Norelgestromin active pharmaceutical ingredient (API) or Norelgestromin finished formulations upon request. The Norelgestromin suppliers may include Norelgestromin API manufacturers, exporters, distributors and traders.
click here to find a list of Norelgestromin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Norelgestromin DMF (Drug Master File) is a document detailing the whole manufacturing process of Norelgestromin active pharmaceutical ingredient (API) in detail. Different forms of Norelgestromin DMFs exist exist since differing nations have different regulations, such as Norelgestromin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Norelgestromin DMF submitted to regulatory agencies in the US is known as a USDMF. Norelgestromin USDMF includes data on Norelgestromin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Norelgestromin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Norelgestromin suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Norelgestromin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Norelgestromin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Norelgestromin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Norelgestromin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Norelgestromin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Norelgestromin suppliers with NDC on PharmaCompass.
Norelgestromin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Norelgestromin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Norelgestromin GMP manufacturer or Norelgestromin GMP API supplier for your needs.
A Norelgestromin CoA (Certificate of Analysis) is a formal document that attests to Norelgestromin's compliance with Norelgestromin specifications and serves as a tool for batch-level quality control.
Norelgestromin CoA mostly includes findings from lab analyses of a specific batch. For each Norelgestromin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Norelgestromin may be tested according to a variety of international standards, such as European Pharmacopoeia (Norelgestromin EP), Norelgestromin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Norelgestromin USP).
LOOKING FOR A SUPPLIER?